Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients

dc.contributor.authorSirera, Guillem
dc.contributor.authorVidela, Sebastià
dc.contributor.authorSaludes, Verónica
dc.contributor.authorCastellà, Eva
dc.contributor.authorSanz, Carolina
dc.contributor.authorAriza, Aurelio
dc.contributor.authorClotet, Bonaventura, 1953-
dc.contributor.authorMartró, Elisa
dc.date.accessioned2022-09-12T10:52:18Z
dc.date.available2022-09-12T10:52:18Z
dc.date.issued2022-08-01
dc.date.updated2022-08-18T12:11:28Z
dc.description.abstractHIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41-70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26-54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0-93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2045-2322
dc.identifier.pmid35915124
dc.identifier.urihttps://hdl.handle.net/2445/188911
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-022-17237-5
dc.relation.ispartofScientific Reports, 2022, vol. 12, num. 1, p. 13196
dc.relation.urihttps://doi.org/10.1038/s41598-022-17237-5
dc.rightscc by (c) Sirera, Guillem et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de pulmó
dc.subject.classificationPersones seropositives
dc.subject.classificationInfeccions per VIH
dc.subject.otherLung cancer
dc.subject.otherHIV-positive persons
dc.subject.otherHIV infections
dc.titlePrevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s41598-022-17237-5.pdf
Mida:
1.13 MB
Format:
Adobe Portable Document Format